Silence Therapeutics

From WikiMD's WELLNESSPEDIA


Silence Therapeutics is a biotechnology company focused on developing therapies that harness the body's natural mechanisms to silence disease-causing genes. The company specializes in RNA interference (RNAi) technology, which is a biological process where RNA molecules inhibit gene expression or translation, effectively silencing targeted genes.

History[edit]

Silence Therapeutics was founded with the aim of advancing RNAi technology to create innovative treatments for a variety of diseases. Over the years, the company has developed a robust pipeline of therapeutic candidates targeting a range of conditions, including rare genetic disorders and cardiovascular diseases.

Technology[edit]

The core technology of Silence Therapeutics is based on RNAi, a process that utilizes small interfering RNA (siRNA) molecules to target and degrade specific messenger RNA (mRNA) molecules, preventing the production of disease-causing proteins. This approach allows for precise targeting of genes involved in disease processes.

RNA Interference[edit]

RNA interference is a natural cellular mechanism that regulates gene expression. It involves the use of double-stranded RNA molecules to trigger the degradation of complementary mRNA, thereby reducing the expression of specific genes. Silence Therapeutics leverages this mechanism to develop therapies that can silence genes associated with various diseases.

Pipeline[edit]

Silence Therapeutics has a diverse pipeline of RNAi-based therapeutics. Some of the key areas of focus include:

  • Rare Genetic Disorders: Developing treatments for conditions caused by specific genetic mutations.
  • Cardiovascular Diseases: Targeting genes involved in the regulation of cholesterol and other factors contributing to heart disease.
  • Other Therapeutic Areas: Exploring RNAi applications in oncology and other fields.

Collaborations[edit]

Silence Therapeutics has established partnerships with several pharmaceutical companies to advance its RNAi technology and expand its therapeutic offerings. These collaborations aim to accelerate the development and commercialization of RNAi-based treatments.

Related pages[edit]



This Biotechnology article is a stub. You can help WikiMD by expanding the page.


Stub icon

This medical article is a stub. You can help WikiMD by expanding the page.

Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Silence_Therapeutics&oldid=6631408"